New pill could cut blood transfusions for MDS patients

NCT ID NCT06304103

Recruiting now Disease control Sponsor: Kind Pharmaceuticals LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests a once-daily pill called AND017 for anemia caused by lower-risk myelodysplastic syndromes (MDS). About 63 participants who do not need frequent transfusions will take the drug to see if it can raise hemoglobin levels or reduce the need for blood transfusions over 24 weeks. The goal is to find a safe and effective dose for this condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AND017 (a drug taken once daily by mouth)
What this could lead to: If it works, this could offer a new daily pill to manage anemia in people with lower-risk MDS, reducing or eliminating the need for blood transfusions.
What could go wrong: This is an early Phase 2 trial with only 63 people, so results may not hold up in larger studies. The drug may not improve hemoglobin enough or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 30003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.